Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
mergers and acquisitions
Biotech
Merck pays $9.2B for owner of flu antiviral J&J rejected
Merck & Co. is spending $9.2 billion for Cidara Therapeutics and its lead influenza antiviral that was dropped by Johnson & Johnson last year.
James Waldron
Nov 14, 2025 8:25am
Pfizer finalizes Metsera buy after contentious Novo bidding war
Nov 13, 2025 12:43pm
Day One pens $285M deal for Mersana
Nov 13, 2025 10:15am
Neuphoria, reeling from ph. 3 fail, mulls buyout from investor
Nov 11, 2025 8:40am
Axsome adds AZ asset through Avenue subsidiary acquisition
Nov 6, 2025 10:50am
Novo Nordisk CEO 'feels' Danish pharma will bag Metsera
Nov 5, 2025 4:20am
